SPHS Sophiris Bio Inc.

1.12
0  -0%
Previous Close 1.12
Open 1.12
Price To Book -8.58
Market Cap 33588991
Shares 30,111,153
Volume 66,640
Short Ratio
Av. Daily Volume 260,523

SEC filingsSee all SEC filings

  1. 8-K - Current report 19505691
  2. CT ORDER - Confidential treatment order 181246420
  3. 8-K - Current report 181237056
  4. 424B5 - Prospectus [Rule 424(b)(5)] 181224325
  5. 8-K - Current report 181224310

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 trial planned. Phase 2b data released December 17, 2018 noted no additional benefit gained with a second administration.
Topsalysin (PRX302)
Localized low to intermediate risk prostate cancer
Phase 3 primary endpoints met - November 2015. Second Phase 3 trial dependent on funding.
Topsalysin (PRX302)
Benign prostatic hyperplasia

Latest News

  1. SPHS: Ready to Move Topsalysin into Phase 3 for Localized Clinically Significant Prostate Cancer…
  2. Sophiris Bio Provides Updates on Phase 2b Localized Prostate Cancer Trial
  3. Does Sophiris Bio Inc (FRA:BFF1) Have A Volatile Share Price?
  4. SPHS: Data from Second Administration of Topsalysin in Phase 2b Trial Anticipated Before End of 2018…
  5. Sophiris Bio to Present at the Piper Jaffray Healthcare Conference
  6. Sophiris Bio Reports Third Quarter 2018 Financial Results and Recent Corporate Highlights
  7. Sophiris Bio to Present at the Cantor Global Healthcare Conference
  8. Sophiris Bio Extends the Interest Only Period under its Loan and Security Agreement
  9. SPHS: Patient Death in Phase 2b Trial Unlikely Related to Topsalysin Treatment…
  10. Today’s Research Reports on Stocks to Watch: Opiant Pharmaceuticals and Sophiris Bio
  11. Sophiris Bio to Present at the H.C. Wainwright 20th Annual Global Investment Conference
  12. Sophiris Bio Updates on Phase 2b Localized Prostate Cancer Trial
  13. SPHS: Ready to Advance Topsalysin into Registration Studies…
  14. Sophiris Bio Reports Second Quarter 2018 Financial Results and Recent Corporate Highlights
  15. SPHS: Interim Data Reported for P2b Study of Topsalysin in Localized Prostate Cancer
  16. Today’s Research Reports on Stocks to Watch: Spectrum Pharmaceuticals and Sophiris
  17. Today's Research Reports on Trending Tickers: Sophiris Bio and Achaogen
  18. Sophiris Bio Reports Top-Line Interim Safety and Biopsy Findings For its Phase 2b Clinical Trial of Topsalysin in Localized Prostate Cancer

SEC Filings

  1. 8-K - Current report 19505691
  2. CT ORDER - Confidential treatment order 181246420
  3. 8-K - Current report 181237056
  4. 424B5 - Prospectus [Rule 424(b)(5)] 181224325
  5. 8-K - Current report 181224310
  6. 10-Q - Quarterly report [Sections 13 or 15(d)] 181178232
  7. 8-K - Current report 181177946
  8. 8-K - Current report 181047142
  9. 10-Q - Quarterly report [Sections 13 or 15(d)] 181017582
  10. 8-K - Current report 181017450